Welcome to our dedicated page for Fortrea Holdings SEC filings (Ticker: FTRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fortrea Holdings Inc. (NASDAQ: FTRE) files a variety of reports and disclosures with the U.S. Securities and Exchange Commission as a public company. This SEC filings page brings those documents together and adds AI-powered summaries to help readers understand the information that Fortrea provides through its regulatory filings.
Fortrea’s filings include current reports on Form 8-K, which disclose material events such as quarterly financial results, tender offers for senior secured notes, amendments to equity inducement award plans and changes in the composition of the board of directors or executive leadership. These 8-Ks often reference accompanying press releases that describe Fortrea’s revenues, net income or loss, adjusted financial measures, guidance and other operating details.
As a NASDAQ-listed issuer in the Professional, Scientific, and Technical Services sector, Fortrea also files annual reports on Form 10-K and quarterly reports on Form 10-Q. These periodic reports provide more comprehensive discussions of the company’s clinical development solutions, risk factors, financial statements and management’s analysis of results. Over time, they document how Fortrea manages its contract research organization activities and capital structure.
On this page, AI-generated highlights can help explain key points from lengthy filings, such as the implications of a debt tender offer, the nature of an inducement award plan, or the significance of board and executive changes. Users can also review information about securities registered under Section 12(b), including Fortrea’s common stock and rights to purchase Series A preferred stock.
In addition, this page provides access to filings that may relate to compensation arrangements, governance policies and other matters relevant to investors and analysts who follow FTRE. Real-time updates from the SEC’s EDGAR system, combined with AI summaries, are intended to make Fortrea’s regulatory disclosures easier to navigate and interpret.
A holder of FTRE common stock filed a notice to sell 881 shares of common stock under Rule 144 through Fidelity Brokerage Services on or about February 10, 2026 on NASDAQ, with an aggregate market value of $12,230.22.
The 881 shares were acquired as restricted stock vesting from the issuer on February 9, 2026, treated as compensation. The notice states that the person selling the securities does not know of any material adverse, nonpublic information about the issuer’s current or prospective operations.
A holder of FTRE common stock filed a notice of proposed sale under Rule 144. The filing covers up to 1,179 common shares, with an aggregate market value of 16,367.11, to be sold through Fidelity Brokerage Services on the NASDAQ, with an approximate sale date of 02/10/2026. The shares were acquired on 02/09/2026 through restricted stock vesting from the issuer as compensation. The filing notes that total common shares outstanding are 92,400,000, which is a baseline figure and not the amount being sold.
A shareholder of FTRE has filed a notice of intent to sell 27,736 shares of common stock under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an indicated aggregate market value of $431,935.49. As context, the filing reports 92,400,000 shares of this class of common stock outstanding.
The securities to be sold were acquired on 01/02/2026 via restricted stock vesting from the issuer as compensation, with the same date listed as the payment date. The section covering securities sold during the past three months does not show additional transactions in this excerpt. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Fortrea Holdings Inc. (FTRE) reported an equity award to one of its directors. On 11/20/2025, the director received 20,916 Restricted Stock Units (RSUs), each representing the right to receive one share of Fortrea common stock at settlement. The RSUs were granted at a price of $0 and are scheduled to vest in full on November 20, 2026. Following this grant, the director beneficially owns 20,916 shares of Fortrea common stock through these RSUs, held in direct form.
Fortrea Holdings Inc. reported the results of its cash tender offer for its 7.500% Senior Secured Notes due 2030. The company had offered to purchase up to $75,744,000 in aggregate purchase price of these notes. Holders tendered more notes than this maximum, and Fortrea accepted $75,743,000 in aggregate principal amount for purchase, based on a Final Proration Factor of 0.154199 and rounding down to the nearest $1,000 of principal. The offer expired at 5:00 p.m., New York City time, on November 18, 2025.
Fortrea Holdings (FTRE) filed its Q3 2025 10‑Q. Revenue rose to $701.3 million from $674.9 million a year ago, and the operating loss narrowed to $8.6 million. For the first nine months, revenue reached $2,062.9 million and net loss was $953.7 million, largely reflecting $797.9 million of goodwill impairments recorded in the first half.
Cash from operations for the nine months was $(15.6) million versus $245.7 million last year; cash ended at $131.3 million. The company sold $300.0 million of receivables under its securitization program and reported unearned revenue of $411.6 million, indicating contracted work in progress. Long‑term debt stood at $1,052.1 million, and Fortrea intends to repurchase up to $75.7 million of its 7.50% senior notes due 2030 pursuant to the asset sale covenant. Q3 segment operating income was $21.1 million.
Fortrea reports one segment (Clinical Services) and noted customer concentration, with one customer accounting for 19.8% of Q3 revenue. On June 11, 2025, the Board adopted a limited-duration stockholder rights plan.
Fortrea Holdings Inc. (FTRE) furnished an 8-K announcing quarterly results. On November 5, 2025, the company issued a press release with financial results for the fiscal quarter ended September 30, 2025, furnished as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished and not deemed filed under the Exchange Act, and is not subject to Section 18 liabilities, nor incorporated by reference except as specifically stated.
William J. Sharbaugh, identified as a director of Fortrea Holdings Inc. (FTRE), submitted an initial Form 3 disclosing that he does not beneficially own any securities of the issuer. The filing notes an Exhibit 24 power of attorney and is submitted as an individual filing on behalf of the reporting person.
Fortrea Holdings Inc. expanded its board and appointed William J. Sharbaugh as a Class III director, with his term running until the 2026 Annual Meeting of Stockholders or until a successor is elected. The board size was increased to eight directors. Mr. Sharbaugh brings more than three decades of pharmaceutical industry experience across finance, operations, manufacturing, quality, and clinical research organizations, and currently serves on several industry boards. At the time of disclosure he was not named to board committees and will be compensated under the company’s non-employee director compensation policy. The company disclosed no related-party transactions or family relationships requiring disclosure and furnished a press release as an exhibit.
Fortrea Holdings Inc. (FTRE) reporting person Robert Parks, Chief Accounting Officer, had Restricted Stock Units (RSUs) settle into common stock and completed a sell-to-cover tax withholding sale. On 09/15/2025, 24,934 RSUs vested and were settled into 24,934 shares at $0 per RSU as part of scheduled vesting. On 09/16/2025, Parks sold 7,338 shares at a weighted-average price of $9.95 to satisfy tax withholding required by the company’s equity plan. After these transactions, Parks beneficially owned 19,046 shares and held an aggregate 67,721 RSUs (remaining unvested). The Form 4 was signed by an attorney-in-fact on 09/17/2025.